(Hypertension. 1999;34:744-747.)
© 1999 American Heart Association, Inc.
Scientific Contributions |
Rostral Ventrolateral Medulla
A Source of Sympathetic Activation in Rats Subjected to Long-Term Treatment With L-NAME
From the Department of Physiology, UNIFESP, Escola Paulista de Medicina, São Paulo, Brazil.
Correspondence to Cássia T. Bergamaschi, Departamento de Fisiologia, Universidade Federal de São Paulo–Escola Paulista de Medicina, Rua Botucatu, 862, CEP 04023-060, São Paulo, SP, Brazil. E-mail cassia{at}fisiocardio.epm.br
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Abstract—The major aim of the present study was to evaluate the role of the rostral ventrolateral medulla (RVLM) in the maintenance of hypertension in rats subjected to long-term treatment with NG-nitro-L-arginine methyl ester (L-NAME) (70 mg/kg orally for 1 week). We inhibited or stimulated RVLM neurons with the use of drugs such as glycine, L-glutamate, or kynurenic acid in urethane-anesthetized rats (1.2 to 1.4 g/kg IV). Bilateral microinjection of glycine (50 nmol, 100 nL) into the RVLM of hypertensive rats produced a decrease in mean arterial blood pressure (MAP) from 158±4 to 71±4 mm Hg (P<0.05), which was similar to the decrease produced by intravenous administration of hexamethonium. In normotensive rats, glycine microinjection reduced MAP from 106±4 to 60±3 mm Hg (P<0.05). Glutamate microinjection into the RVLM produced a significant increase in MAP in both hypertensive rats (from 157±3 to 201±6 mm Hg) and normotensive rats (from 105±5 to 148±9 mm Hg). No change in MAP was observed in response to kynurenic acid microinjection into the RVLM in either group. These results suggest that hypertension in response to long-term L-NAME treatment is dependent on an increase in central sympathetic drive, mediated by RVLM neurons. However, glutamatergic synapses within RVLM are probably not involved in this response.
Key Words: vasomotor system • rostral ventrolateral medulla • hypertension, experimental • L-NAME • glutamate
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
It is well known that pharmacological inhibition of nitric oxide synthase (NOS) produces acute and chronic hypertension, but the mechanisms mediating the hypertension are not completely understood.1 2 3 4 5 Although this hypertension was first attributed solely to inhibition of endothelial nitric oxide (NO), more recently a large body of evidence suggests the involvement of the central nervous system. In particular, inhibition of neuronal NO may contribute to the hypertension induced by long-term treatment with NG-nitro-L-arginine methyl ester (L-NAME).6 7 8
Contradictory results have been reported about the role of the sympathetic nervous system (SNS) in the maintenance of hypertension induced by NOS blockade. In some studies, blockade of the SNS had no effect on this hypertension,9 10 whereas other studies using similar methods showed a significant reduction in hypertension.6 8 11
Because the rostral ventrolateral medulla (RVLM) contains sympathetic premotor neurons and is considered to be the final common pathway for several cardiovascular responses and for the control of sympathetic vasomotor tone, it is reasonable to suggest that these premotor neurons may be involved in the maintenance of hypertension due to NOS inhibition.12 To test this hypothesis, we performed a study in which we compared the effects of pharmacological inhibition of the RVLM with the effects of ganglionic blockade on mean arterial pressure (MAP) and heart rate (HR) in hypertensive and control groups. We also tested the role of glutamatergic synapses within the RVLM in this model.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Experiments were performed on 51 male Wistar rats (weight 250 to 300 g) provided by the Central Animal House of the Federal University of São Paulo, Brazil. All animal procedures were conducted according to the "Guidelines for the Ethical Care of Experimental Animals" and were approved by the Institutional Animal Care and Use Committee. On arrival, the rats were randomly assigned to 1 of 2 groups: normotensive or hypertensive. Hypertensive animals were treated orally with L-NAME (70 mg/kg) for 7 days. Normotensive animals received treatment with vehicle (distilled water) only. After the end of treatment, rats were anesthetized with ketamine and xylazine (40 and 20 mg/kg IP, respectively) and instrumented with femoral venous and arterial catheters constructed from PE-50 and PE-10 tubing filled with heparinized saline for drug injection and arterial pressure recording, respectively. Catheters were externalized through the nape of the animal's neck. After surgery, the rats were returned to their home cage for recovery. All experiments were performed
24 hours after
surgery. On the day of the experiment, arterial blood
pressure and HR were recorded in awake, free-moving rats, and the
animals were then anesthetized very slowly with urethane (1.2
to 1.4 g/kg IV). Animals showing a decrease in blood pressure with
anesthesia were not used in the experiment. The
trachea was cannulated for artificial ventilation, and pulsatile
arterial blood pressure (ABP) was recorded with a P23XL
transducer (Statham Instruments Division, Gould Inc) connected to an
RS3400 recorder (Record System Division, Gould Inc). We
obtained MAP by filtering the ABP signal, and we obtained HR from a
cardiotachometer (ECG/Biotach, Gould Inc) triggered by the pulse wave.
Body temperature was maintained at 37°C with the use of a
heating table. Rats were placed prone in a stereotaxic apparatus (David Kopf Instruments) with the bite bar 12 mm below the interaural line. An occipital craniotomy was performed to expose the dorsal surface of the brain stem and cerebellum. We then opened the dura and retracted it by exposing the obex, whose vertex was taken as a landmark for the stereotaxic coordinates.
Microinjection Procedures
The rostral ventrolateral medulla was identified by injection of
L-glutamate with stereotaxic coordinates
3.0 mm rostral, 1.8 mm lateral, and 3 mm ventral to the
obex. Microinjections into the RVLM were performed with glass
micropipettes (tip diameter 
20 µm) connected to a handheld
syringe. We monitored the injected volume by observing the meniscus
through a dissecting microscope with a calibrated graticule. Drugs were
bilaterally injected in a volume of 100 nL over a period of 10 to 20
seconds. Microinjections of L-glutamate (10 nmol), glycine
(50 nmol), and kynurenic acid (2 nmol) were diluted in saline, and the
pH of all solutions was adjusted to 7.4. Microinjections of vehicle
alone produced no changes in blood pressure or HR in hypertensive
or normotensive animals. All drugs used were from Sigma Chemical
Co.
At the end of the experiments, 100 nL of 2% Evans blue dye was injected bilaterally into the RVLM, and the brain stem was removed and stored in 10% formalin. The brain stem was sectioned along the coronal plane (50 µm) and stained with neutral red. Microinjection sites were identified by deposition of Evans blue. Figure 1 is representative of the dye distribution.
|
Experimental Protocol
The RVLM was identified by injection of 5 nmol of
L-glutamate, and only 1 more injection was made thereafter
(glutamate, glycine, or kynurenic acid). At the end of the experiment,
hexamethonium bromide (10 mg/kg) was injected
intravenously.
Statistical Analysis
All values are expressed as mean±SEM. The significance of
changes in MAP or HR after microinjection was determined within each
group by Student's paired t test. Differences between
groups were assessed by 1-way ANOVA followed by the Kruskal-Wallis
test. Differences were considered significant at
P<0.05.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Rats chronically treated with L-NAME developed a significant increase in MAP (157±5 mm Hg) compared with the vehicle-treated group (105±4 mm Hg).
Effects of Microinjections of Glycine Into the RVLM
Microinjections of the inhibitory amino acid glycine
into the RVLM of hypertensive rats (n=7) resulted in a significant
decrease in MAP (from 158±4 to 71±4 mm Hg; P<0.05)
and HR (from 401±32 to 330±31 bpm; P<0.05), as shown in
Figure 2. MAP began to decrease
immediately after the microinjection, reached a minimum value within
6.17±1.83 minutes, and then gradually recovered over 45±16.31
minutes.
|
In control normotensive rats (n=6), microinjections of glycine into the RVLM decreased MAP (from 106±4 to 60±3 mm Hg; P<0.05), and bradycardia was also observed (from 440±19 to 377±55 bpm; P<0.05). The response peaked at 2.2±0.7 minutes, and recovery occurred within 10.6±4.8 minutes. An important finding was that the MAP levels reached by normotensive and hypertensive rats were not significantly different (60±3 mm Hg in normotensive animals and 71±4 mm Hg in hypertensive animals), as shown in Figure 2.
Effects of Microinjection of Glutamate Into the RVLM
A significant pressor response followed glutamate microinjections
into the RVLM of hypertensive rats (n=7), as shown in Figure 3. The increase in MAP (from 157±3 to
201±6 mm Hg; P<0.05) was accompanied by bradycardia
(from 407±18 to 312±19 bpm; P<0.05). The response began
during the microinjection period, peaked at 2 minutes, and remained
above the basal level for 33 minutes. When glutamate was injected into
normal rats (n=6), it also produced a significant increase in MAP (from
105±5 to 148±9 mm Hg) and a reduction in heart rate from
380±49 to 363±53 bpm (P<0.05). An important result
was that no significant difference in pressor response was observed
between the hypertensive and normotensive groups.
|
Effects of Microinjections of the Broad-Spectrum Glutamate
Antagonist Kynurenic Acid Into the RVLM
Bilateral microinjection of kynurenic acid into the RVLM of
hypertensive animals (n=7) did not elicit any change in MAP or HR,
which indicates that glutamatergic synapses within the RVLM are not
important for the maintenance of high blood pressure in this
model. The same result was observed when kynurenic acid was
microinjected into control animals (n=6).
Intravenous Injection of the Ganglion Blocker
Hexamethonium
Figure 4 shows the response to
intravenous injection of hexamethonium in
hypertensive (n=7) and normotensive (n=5) rats.
Hexamethonium produced a significant decrease in MAP in
both groups (from 140±8 to 69±4 mm Hg [P<0.05] in
hypertensive rats and from 100±4 to 60±5 mm Hg
[P<0.05] in control rats). There was no significant
difference between groups in the level of MAP that was reached. Another
finding was that the maximum hypotensive effect of
hexamethonium was the same as that of glycine in both
normotensive and hypertensive animals.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The present study clearly shows that the SNS plays a major role in the maintenance of hypertension induced by long-term L-NAME treatment. It also seems reasonable to suggest that the RVLM is the main source of this sympathetic activation. Importantly, all vasomotor tone generation in the chronic L-NAME model is dependent on the sympathetic system, because either intravenous hexamethonium administration or glycine microinjection into the RVLM reduced MAP to a level comparable to that seen after acute spinal cord transection in both groups (normotensive and hypertensive).
Even though the SNS is primarily involved in this model of hypertension, we observed no evidence of tonic activity of glutamatergic synapses within the RVLM. In a previous study of rats with chronic renal hypertension,13 we showed that RVLM activity was also involved in the maintenance of hypertension, although in that study, glutamatergic synapses in the RVLM appeared to have strong tonic activity.
There is increasing evidence to suggest that the SNS may play a primary role in the pathogenesis of essential hypertension and in the long-term regulation of arterial pressure and that effects may be dependent, in part, on the activity of a small group of premotor neurons localized in the RVLM.13 14 15 16 In spontaneously hypertensive rats, for example, there is enhanced sympathetic reactivity in response to RVLM stimulation with glutamate.14
The role of the SNS in hypertension due to NOS inhibition is controversial. Acute inhibition of the SNS in this model has been shown to produce either a substantial fall or a small change in blood pressure.6 8 9 10 However, acute or chronic ganglionic blockade induces a fall in blood pressure in rats subjected to long-term treatment with L-NAME, which suggests that an enhanced sympathetic drive must be involved in this model of hypertension.6 8 At some point, the hypertension produced by NOS inhibition changes from an endothelial peripheral vasoconstriction to a model that apparently is mainly dependent on activity of the SNS. Why and when this happens remain to be determined.
We should also consider the involvement of the brain NO system in this model. Iadecola et al17 found that systemic administration of L-NAME leads to partial inhibition of brain NOS catalytic activity over a period of 1 to 2 hours that persists for several days. Recent immunocytochemical studies18 19 20 reported high concentrations of NOS within specific regions of the brain, some of which are involved in cardiovascular regulation. Microinjection of NO or NO donors in the paraventricular nucleus results in decreases in blood pressure, which indicates the potential of NO to influence cardiovascular control mechanisms through actions in this area.21 It has been shown that inhibition of NOS in the nucleus tractus solitarii increases sympathetic tone and blood pressure in rabbits.22 It has also been suggested that NO modulates the baroreceptor reflex control of HR in spontaneously hypertensive and Wistar-Kyoto rats at the level of the nucleus tractus solitarii.23
On the other hand, several studies have related the hypertension induced by NOS inhibition to the angiotensin system.2 9 24 25 Long-term angiotensin II inhibition seems to be able to prevent and reverse hypertension.9 24 It has also been suggested that hypertension induced by L-NAME treatment is sustained by an interaction of several mechanisms, including activation of the SNS and the renin-angiotensin system.10 26 27 Because it is well known that the brain angiotensin system has excitatory effects in several areas, including the RVLM, this system may be involved in this model of hypertension.28 29 30 Another possibility is that NO could be acting as a neurotransmitter or neuromodulator in the RVLM to produce cardiovascular effects.31 32
We know that sympathetic vasomotor tone depends critically on tonic
activity of RVLM premotor neurons.12 33 There is a large
body of evidence showing that the functional integrity of the RVLM is
essential for the maintenance of basal vasomotor
tone.12 33 Electrolytic lesions or chemical inactivation
of RVLM neurons by inhibitory amino acids such as glycine
or 
-aminobutyric acid (GABA) results in a collapse of blood pressure
similar to that usually obtained in animals with acute spinal
injury.12 33 34
In summary, the present study demonstrated that in rats made hypertensive by long-term L-NAME treatment, the RVLM is the major source of vasomotor tone. However, these data provide no definitive answer as to where L-NAME acts in the central nervous system.
|
Acknowledgments |
|---|
This research was supported by Fundação de Amparo à Pesquisa d. Estado de São Paulo (FAPESP) and Consello Nacional de Desenvolvimento Cienifico e Tecnológico (CNP).
Received May 8, 1999; first decision June 22, 1999; accepted July 2, 1999.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Ribeiro MO, Antunes E, De Nucci, Lovisolo SM, Zatz R. Chronic inhibition of nitric oxide synthesis: a new model of arterial hypertension. Hypertension. 1992;20:298–303.
2.
Jover B, Herizi A, Ventre F, Dupont M, Mimran A.
Sodium and angiotensin in hypertension induced by chronic
nitric oxide inhibition. Hypertension. 1993;21:944–948.
3. Baylis C, Mitruka B, Deng A. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest. 1992;90:278–281.
4. Lahera V, Salazar J, Salom MG, Romero JC. Deficient production of nitric oxide induces volume-dependent hypertension. J Hypertens. 1992;10(suppl):S173–S177.
5.
Zatz R, Baylis C. Chronic nitric oxide inhibition
model six years on. Hypertension. 1998;32:958–964.
6. Cunha RS, Cabral AM, Vasquez EC. Evidence that the autonomic nervous system plays a major role in the L-NAME induced hypertension in conscious rats. Am J Hypertens. 1993;6:806–809.[Medline] [Order article via Infotrieve]
7.
Sander M, Hansen PG, Victor RG. Sympathetic mediated
hypertension caused by chronic inhibition of nitric oxide.
Hypertension. 1995;26:691–695.
8.
Sander M, Hansen J, Victor RG. The sympathetic nervous
system is involved in the maintenance but not initiation of the
hypertension induced by
N
-nitro-L-arginine
methyl ester. Hypertension. 1997;30(pt 1):64–70.
9.
Qiu C, Engels K, Baylis C. Angiotensin II
and alpha 1-adrenergic tone in chronic nitric oxide blockade-induced
hypertension. Am J Physiol. 1994;266:R1470–R1476.
10.
Bank N, Aynedjian HS, Khan GA. Mechanism of
vasoconstriction induced by chronic inhibition of nitric oxide in
rats. Hypertension. 1994;24:322–328.
11.
Zanchi A, Schaad NC, Osterheld MC, Grouzmann E,
Nussberger J, Brunner HR, Waeber B. Effects of chronic NO synthase
inhibition in rats on renin-angiotensin system and
sympathetic nervous system. Am J Physiol. 1995;268:H2267–H2273.
12. Dampney RAL. The subretrofacial vasomotor nucleus: anatomical, chemical and pharmacological properties and role in cardiovascular regulation. Prog Neurobiol. 1994;42:197–227.[Medline] [Order article via Infotrieve]
13.
Bergamaschi CT, Campos RR, Schor N, Lopes OU. Role of
the rostral ventrolateral medulla in maintenance of blood
pressure in rats with Goldblatt hypertension. Hypertension. 1995;26:1117–1120.
14.
Yang TLC, Chai CY, Yen CT. Enhanced sympathetic
reactivity to glutamate stimulation in medulla oblongata of
spontaneously hypertensive rats. Am J Physiol. 1995;268:H1499–H1509.
15. Osborn JW, Plato CF, Gordin E, He XR. Long-term increases in renal sympathetic nerve activity and hypertension. Clin Exp Pharmacol Physiol. 1997;24:72–76.[Medline] [Order article via Infotrieve]
16. Osborn JW. The sympathetic nervous system and long-term regulation of arterial pressure: what are the critical questions? Clin Exp Pharmacol Physiol. 1997;24:68–71.[Medline] [Order article via Infotrieve]
17. Iadecola C, Xu X, Zhang F, Hu J, El-Fakahany EE. Prolonged inhibition of brain nitric oxide synthase by short-term systemic administration of nitro-L-arginine methyl ester. Neurochem Res. 1994;19:501–505.[Medline] [Order article via Infotrieve]
18. Knowles RG, Moncada S. Nitric oxide synthase in mammals. Biochem J. 1994;298:249–258.
19. Dun NJ, Dun SL, Förstermann U. Nitric oxide synthase immunoreactivity in rat pontine medullary neurons. Neuroscience. 1994;59:429–445.[Medline] [Order article via Infotrieve]
20. Vincent SR. Nitric oxide: a radical neurotransmitter in the central nervous system. Prog Neurobiol. 1994;42:129–160.[Medline] [Order article via Infotrieve]
21.
Horn T, Smith PM, McLaughlin BE, Bauce L, Marks GS,
Pittman QJ, Ferguson AV. Nitric oxide actions in
paraventricular nucleus: cardiovascular and
neurochemical implications. Am J Physiol. 1994;266:R306–R313.
22.
Harada S, Tokunaga S, Momohara M, Masaki H, Tagawa T,
Imaizumi T. Inhibition of nitric oxide in the nucleus tractus
solitarius increases renal sympathetic nerve activity in rabbits.
Circ Res. 1993;72:511–516.
23. Pontieri V, Venezuela MK, Scavone C, Michelini LC. Role of endogenous nitric oxide in the nucleus tractus solitarii and baroreflex control of heart in spontaneously hypertensive rats. J Hypertens. 1998;16:1993–1999.[Medline] [Order article via Infotrieve]
24.
Pollock DM, Polakowski JS, Divish BJ, Opgenorth TJ.
Angiotensin blockade reverses hypertension during long-term
nitric oxide synthase inhibition. Hypertension. 1993;21:660–666.
25. Morton JJ, Beattie EC, Speirs A, Gulliver F. Persistent hypertension following inhibition of nitric oxide formation in the young Wistar rat: role of renin and vascular hypertrophy. J Hypertens. 1993;11:1083–1088.[Medline] [Order article via Infotrieve]
26. Qiu C, Muchant D, Bierwaltes WH, Racusen L, Baylis C. Evolution of chronic nitric oxide inhibition hypertension: relationship to renal function. Hypertension. 1998;31(pt 1):21–26.
27. Dampney RAL, Hirooka Y, Potts PD, Head GA. Functions of angiotensin peptides in the rostral ventrolateral medulla. Clin Exp Pharmacol Physiol. 1996;23:S105–S111.
28.
Muratani H, Ferrario CM, Averill DB. Ventrolateral
medulla in spontaneously hypertensive rats: role of
angiotensin II. Am J Physiol. 1993;264:R388–R395.
29. Muratani H, Teruya H, Sesoko S, Takishita S, Fukiyama K. Brain angiotensin and circulatory control. Clin Exp Pharmacol Physiol. 1996;23:458–464.[Medline] [Order article via Infotrieve]
30. Martins-Pinge MC, Baraldi-Passy I, Lopes OU. Excitatory effects of nitric oxide within the rostral ventrolateral medulla of freely moving rats. Hypertension. 1997;39(pt 2):704–707.
31. Hirooka Y, Polson JW, Dampney RAL. Pressor and sympathoexcitatory effects of nitric oxide in the rostral ventrolateral medulla. J Hypertens. 1996;14:1317–1324.[Medline] [Order article via Infotrieve]
32.
Spyer KM. Central nervous mechanisms contributing to
cardiovascular control. J Physiol. 1994;474:1–19.
33.
Guertzenstein PG, Silver A. Fall in blood pressure
produced from discrete regions of the ventral surface of the medulla by
glycine and lesions. J Physiol. 1974;242:489–503.
34. Ross CA, Ruggiero DA, Park DH, Joh TH, Sved AF, Pardal JF, Saavedra JM, Reis DJ. Tonic vasomotor control by the rostral ventrolateral medulla: effect of electrical or chemical stimulation of the area containing C1 adrenaline neurons on arterial pressure, heart rate and plasma catecholamines and vasopressin. J Neurosci. 1984;4:474–494.[Abstract]
This article has been cited by other articles:
 |
|
 |
|
  K. Ito, Y. Hirooka, T. Kishi, Y. Kimura, K. Kaibuchi, H. Shimokawa, and A. Takeshita Rho/Rho-Kinase Pathway in the Brainstem Contributes to Hypertension Caused by Chronic Nitric Oxide Synthase Inhibition Hypertension, February 1, 2004; 43(2): 156 - 162. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. Reckelhoff and J. C. Romero Role of oxidative stress in angiotensin-induced hypertension Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2003; 284(4): R893 - R912. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Y.H. Chan, L.-L. Wang, Y.-M. Chao, and S. H.H. Chan Downregulation of Basal iNOS at the Rostral Ventrolateral Medulla Is Innate in SHR Hypertension, March 1, 2003; 41(3): 563 - 570. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. P. Patel, Y.-F. Li, and Y. Hirooka Role of Nitric Oxide in Central Sympathetic Outflow Experimental Biology and Medicine, October 1, 2001; 226(9): 814 - 824. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Colombari, M. A. Sato, S. L. Cravo, C. T. Bergamaschi, R. R. Campos Jr, and O. U. Lopes Role of the Medulla Oblongata in Hypertension Hypertension, September 1, 2001; 38(3): 549 - 554. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Eshima, Y. Hirooka, H. Shigematsu, I. Matsuo, G. Koike, K. Sakai, and A. Takeshita Angiotensin in the Nucleus Tractus Solitarii Contributes to Neurogenic Hypertension Caused by Chronic Nitric Oxide Synthase Inhibition Hypertension, August 1, 2000; 36(2): 259 - 263. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||